Cargando…
Efficacy of Anti-Interleukin-2 Receptor Antibody in Reducing the Incidence of Acute Rejection After Renal Transplantation
Autores principales: | Liborio, Alexandre Braga, Leite, Tacyano Tavares |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Kowsar
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3614313/ https://www.ncbi.nlm.nih.gov/pubmed/23573511 http://dx.doi.org/10.5812/numonthly.7279 |
Ejemplares similares
-
Efficacy of Anti-Interleukin-2 Receptor Antibody (Daclizumab) in Reducing the Incidence of Acute Rejection After Renal Transplantation
por: Saghafi, Hossein, et al.
Publicado: (2012) -
Anti-interleukin-2 receptor antibodies—basiliximab and daclizumab—for the prevention of acute rejection in renal transplantation
por: Sageshima, Junichiro, et al.
Publicado: (2009) -
Bortezomib-Containing Multimodality Treatment for Antibody-Mediated Rejection with Anti-HLA and Anti-AT1R Antibodies after Kidney Transplantation
por: Iesari, Samuele, et al.
Publicado: (2017) -
LIGHT/BTLA polymorphisms and antibody-mediated-rejection after heart transplantation
por: Marrón-Liñares, Grecia M., et al.
Publicado: (2018) -
Anti‐interleukin‐6 antibody clazakizumab in late antibody‐mediated kidney transplant rejection: effect on cytochrome P450 drug metabolism
por: Mühlbacher, Jakob, et al.
Publicado: (2021)